


Innovation for Life

We invite you to our open innovation ecosystem.

IDC (Innovative Discovery Center) aims to foster growth towards an 'Open Innovation Center'. Through exchange, collaboration, and convergence of science and technology, IDC strives to advance a future that contributes to human life. Our value grows through community efforts.

We will achieve scientific accomplishments through mutual contributions.







We connect your great inspirations together.

We are driven by the aspiration to serve as catalysts in uniting the extraordinary inspirations that span across the globe. By nurturing a network of open connections among diverse scientific endeavors, our aim is to unveil the hidden treasures of potential, causing them to rise and shimmer upon the tranquil surface of water, evoking a sense of awe and wonder.

IDC is located in Busan, a beautiful coastal Metropolitan city in South Korea.

Let's connect our futures together.

IDC is fostering its own potential by leveraging the "fast drop & go" strategy in developing its pipeline of biosimilars and first-in-class therapeutics. We are actively pursuing collaborations with diverse universities and research institutions to establish an open ecosystem.

We seek to connect and harmonize scientific experiences and inspirations, while fostering an environment of open innovation where the value of new modalities can grow and evolve together. Discover the balance between life and work in Busan. Busan has been chosen as one of the world's best traveling city by National Geographic in 2023.

Innovative Drug Pipeline

| | | | FDA FDA EMA MFDS |
|----------------------------|--------------------------|--------------------------------------|-----------------------|
| First-in-class | Ulenistamab (PBP1510) | Pancreatic cancer, Ovarian cancer | Clinical (Phase 1/2a) |
| | PBP1710 | Solid tumor | Preclinical |
| | IDC111 | Solid tumor | Basic Research |
| Bispecific Antibody | IDC001 | Solid tumor | Basic Research |
| | IDC002 | Solid tumor | Basic Research |
| | IDC003 | Solid tumor | Basic Research |
| | IDC005 | Solid tumor | Discovery |
| | IDC007 | Critical immune disorders | Discovery |
| | IDC008 | Solid tumor | Discovery |
| | IDC009 | Solid tumor | Discovery |
| | IDC010 | Immune disease | Discovery |
| Novel Concept Antibody | IDC331 | Solid tumor | Discovery |
| | IDC332 | Solid tumor | Discovery |
| | IDC333 | Solid tumor | Discovery |
| | IDC334 | Solid tumor | Discovery |
| Antibody Drug Conjugate | IDC441 | Solid tumor | Basic Research |

First-in-Class Antibody PBP1510 (Ulenistamab)



- Development stage: Phase 1/2a (EU, USA & Asia)
- Indication: Pancreatic cancer, Ovarian cancer
- Orphan Drug Designation by FDA, EMA, MFDS
- Fast Track Designation by FDA POA DESIGNATION FOR PAST TRACK DESIGNATION

First-in-Class Antibody PBP1710 (Anti-CTHRC1)

- Development stage: Preclinical
- Indication : Solid tumors
- Patent registered in Korea in January 2023

First-in-Class PAUF-detecting Diagnostic Kit

A Powerful Tool for Screening and Detection of pancreatic Cancer

Diagnosis PAUF detection in blood as pancreatic cancer screening

- Carbohydrate antigen 19-9(CA19-9) is the only approved biomarker for Pancreatic cancer so far,
- but it has low specificity.

 The novel diagnostic method exhibits high sensitivity and specificity in detecting PAUF. In our preliminary data, PAUF showed a superior diagnostic power that can overcome the weaknesses of current biomarker in pancreatic cancer.



FAST ORPHAN DRUG ORPHAN DRUG ORPHAN DRUG

The World's First Biomarker-based Diagnostic Test for Pancreatic Cancer Early Detection Inviting Clinical Laboratories for LDT partnership

